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INTRODUCTION
Prostate cancer (PCa) is the second most common cancer and 
the fifth leading cause of cancer-related deaths in males world-
wide.1 Death from PCa is typically the result of castration-re-
sistant prostate cancer (CRPC), a clinical state in which disease 
progression occurs despite maintenance of castrate serum 
testosterone levels.2,3 According to recent analyses, approxi-
mately 84% of CRPC patients present with metastatic disease 
at the time of diagnosis,4 and patients with metastatic CRPC 
(mCRPC) are expected to survive up to 18 to 19 months.5
CRPC was once regarded as androgen-insensitive or hor-
mone-refractory; however, it is now widely accepted that an-
drogen receptor (AR) signaling activity is persistent in the pros-
tate in CRPC and that residual androgens continue to drive AR 
signaling activity.6-10 Various molecular studies have shown that 
tumor progression in CRPC is related to AR-associated signal-
ing mechanisms.11 Reported mechanisms include AR overex-
pression and amplification, AR mutations, and increased AR li-
gand expression in the surrounding stroma. According to these 
mechanisms, the increase in AR protein sensitizes PCa cells to 
Survival Outcomes of Concurrent Treatment 
with Docetaxel and Androgen Deprivation Therapy 
in Metastatic Castration-Resistant Prostate Cancer
Ho Seong Jang, Kyo Chul Koo, Kang Su Cho, and Byung Ha Chung
Department of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Purpose: Docetaxel-based chemotherapy (DTX) improves overall survival (OS) of men with metastatic castration-resistant pros-
tate cancer (mCRPC). Considering the potential existence of androgen receptors that remain active at this stage, we aimed to assess 
the impact of the combined use of androgen deprivation therapy (ADT) with DTX for mCRPC.
Materials and Methods: We performed a single-institutional retrospective analysis of patients with mCRPC who received either 
DTX alone (DTX group, n=21) or concurrent DTX and ADT (DTX+ADT group, n=26) between August 2006 and February 2014. 
All patients received DTX doses of 75 mg/m2 every three weeks for at least three cycles. In the DTX+ADT group, all patients used 
luteinizing hormone releasing hormone agonist continuously as a concurrent ADT.
Results: The median follow-up period was 24.0 months (interquartile range 12.0–37.0) for the entire cohort. The median radio-
graphic progression-free survival (rPFS) was 9.0 months and 6.0 months in the DTX+ADT and DTX groups, respectively (log-rank 
p=0.036). On multivariable Cox regression analysis, concurrent administration of ADT was the only significant predictor of rPFS 
[hazard ratio (HR)=0.525, 95% confidence intervals (CI) 0.284–0.970, p=0.040]. The median OS was 42.0 and 38.0 months in the 
DTX+ADT and DTX groups, respectively (log-rank p=0.796). On multivariable analysis, hemoglobin level at the time of DTX initi-
ation was associated with OS (HR=0.532, 95% CI 0.381–0.744, p<0.001).
Conclusion: In chemotherapy-naive patients with mCRPC, the combined use of ADT with DTX improved rPFS. Our result sug-
gests that the concurrent administration of ADT and DTX is superior to DTX alone.
Key Words:  Prostatic neoplasms, castration-resistant; neoplasm metastasis; disease-free survival; docetaxel; drug therapy, com-
bination; gonadotropin-releasing hormone
Yonsei Med J 2016 Sep;57(5):1070-1078
http://dx.doi.org/10.3349/ymj.2016.57.5.1070
Original Article 
pISSN: 0513-5796 · eISSN: 1976-2437
Received: December 3, 2015   Revised: January 19, 2016
Accepted: February 17, 2016
Corresponding author: Dr. Byung Ha Chung, Department of Urology, Gangnam 
Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gang-
nam-gu, Seoul 06273, Korea.
Tel: 82-2-2019-3470, Fax: 82-2-3462-8887, E-mail: chung646@yuhs.ac
•The authors have no financial conflicts of interest.
© Copyright: Yonsei University College of Medicine 2016
This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0) which permits unrestricted non-commercial use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
1071http://dx.doi.org/10.3349/ymj.2016.57.5.1070
Ho Seong Jang, et al.
respond to low levels of ligands,12,13 and AR mutations are as-
sociated with production of a receptor that is more sensitive to 
native ligands.14 In this regard, discontinuation of androgen de-
privation therapy (ADT) in patients with CRPC who have not 
undergone surgical castration could result in tumor growth 
and proliferation. However, there are drawbacks to maintain-
ing ADT. It has been reported that continuation of ADT is as-
sociated with serious health problems–coronary heart disease, 
myocardial infarction, fracture, anemia, and diabetes–and thus 
can affect the survival outcomes of patients.15-18
In terms of survival advantage, the benefits of concurrent 
administration of ADT in CRPC patients under cytotoxic che-
motherapy are debatable. Retrospective reviews of trials by the 
Eastern Cooperative Oncology Group (ECOG) and the South-
west Oncology Group (SWOG) have been performed, and they 
provided conflicting results with regard to survival.19,20 Due to 
the absence of tangible results from related studies, concur-
rent administration of luteinizing hormone-releasing hormone 
agonist for CRPC patients under cytotoxic chemotherapy can-
not be reimbursed by the Korean National Health Insurance 
system under the present guidelines. Considering the poten-
tial presence of ARs that remain active at this stage of the dis-
ease, we sought to assess the impact of the combined use of 
ADT and cytotoxic chemotherapy, particularly docetaxel-based 
chemotherapy (DTX) for mCRPC.
MATERIALS AND METHODS
Study sample
This retrospective study included data from a total of 199 con-
secutive patients with mCRPC who received DTX at the De-
partment of Urology, Yonsei University Health System (Seoul, 
Korea), between August 2006 and February 2014. Collection 
of the retrospective data used in the study was approved by 
the Institutional Ethics Committee after reviewing the proto-
col and procedures employed (2009-0131-001). The study was 
carried out in lieu of a formal ethics committee and followed 
the principles of the Helsinki Declaration.
Patients with the following criteria were included in the 
present analysis: 1) histologically confirmed adenocarcinoma 
of the prostate with clinical or radiologic evidence of metastat-
ic disease and defined as CRPC according to the European As-
sociation of Urology guidelines 2011,21 2) ECOG performance 
status ≤2, 3) computed tomography or magnetic resonance 
imaging, and radionuclide bone scans performed at every three 
cycles of DTX, 4) serum prostate specific antigen (PSA) levels 
measured at each cycle, and 5) adequate bone marrow and or-
gan function. Patients were excluded if they received cytotoxic 
chemotherapy or radioisotope therapy before the administra-
tion of docetaxel or if they had incomplete follow-up data, re-
duced doses of docetaxel, serious or uncontrolled concomitant 
medical illness, history of other cancer within five years, or evi-
dence of central nervous system metastasis. Additionally, pa-
tients who received less than three cycles of DTX were exclud-
ed due to the possibility of a PSA surge.
Of the 199 mCRPC patients who received DTX, 47 fulfilled 
the criteria described above, and 152 patients were excluded 
for the following reasons: prior cytotoxic chemotherapy (n=23), 
dose reduction of docetaxel (n=82), combination with immu-
notherapy or other cytotoxic chemotherapy agents (n=25), and 
less than three cycles of DTX (n=22). The 47 included patients 
were divided into two groups: those who received DTX with 
ADT (DTX+ADT group, n=26), and those who received DTX 
without ADT (DTX group, n=21). 
Medical records were reviewed for the following characteris-
tics: patient age, body mass index (BMI), Gleason score, tumor-
node-metastasis classification of the American Joint Commit-
tee on Cancer,22 neoadjuvant treatments, responses to prior an-
tiandrogen therapies, ECOG performance status, baseline he-
moglobin (Hb), neutrophil-to-lymphocyte ratio, albumin, PSA 
levels, presence of visceral metastases, and extent of the dis-
ease.
Treatment
All patients received docetaxel plus prednisone therapy with or 
without ADT. The regimen consisted of docetaxel (75 mg/m2), 
which was administered through intravenous infusion once on 
day 1 every 3 weeks, plus oral prednisolone 5 mg twice daily 
starting on day 1 and continuing throughout the treatment.
DTX continued until uncontrolled toxicity, disease progres-
sion, planned termination of individual patient, death, or treat-
ment refusal by the patient. The National Cancer Institute Com-
mon Toxicity Criteria version 4.0 was used to evaluate the toxi-
city during each cycle.23
Study endpoints
The primary endpoints were biochemical progression-free 
survival (bPFS) and radiographic progression-free survival 
(rPFS). The secondary endpoint was overall survival (OS). Bio-
chemical progression was defined as a >50% increase from the 
PSA nadir, with a minimum increase of 5 ng/mL.24 The PSA na-
dir was defined as the lowest PSA level achieved during DTX. 
The time to biochemical progression was assessed between 
the day of treatment initiation and biochemical progression. 
The time to radiographic progression was defined as the time 
interval from the day of DTX initiation to the first occurrence 
of either progression on imaging studies. Progression on bone 
scans was assessed according to the Prostate Cancer Working 
Group (PCWG)-2 criteria,25 and soft tissue progression was 
evaluated with reference to the Response Evaluation Criteria in 
Solid Tumors version 1.1.26 OS was calculated from the date of 
DTX initiation to that of death from any cause. For all patients, 
survival and cause of death were investigated based on the 
National Cancer Registry Database or institutional electronic 
medical records.
http://dx.doi.org/10.3349/ymj.2016.57.5.10701072
Concurrent ADT during Docetaxel Chemotherapy
Statistical analysis
The descriptive values of the variables are expressed as medi-
an and interquartile range (IQR) according to the results of 
normality testing. Differences in baseline characteristics were 
compared between groups using a chi-square test or Fisher’s 
exact test for categorical variables and the Mann-Whitney U 
test for continuous variables.
rPFS, OS, and bPFS were calculated and analyzed using the 
Kaplan-Meier method and the log-rank test. Univariable and 
multivariable analyses used Cox proportional hazards mod-
els. Factors associated with progression or mortality with a p 
value of less than 0.20 on univariable analyses were entered in 
the multivariable model, and nonsignificant factors were re-
moved by means of a backward-elimination procedure. The 
hazard ratio (HR) and 95 % confidence intervals (CI) were es-
timated for each variable.
All of the tests were two-sided, and p<0.05 was considered 
to be statistically significant. All statistical analyses were per-
formed using SPSS version 18 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient demographics are presented in Table 1. Both groups 
were similar in terms of age, BMI, pretreatment laboratory val-
ues, stage and grade, extent of metastasis, duration of ADT prior 
to DTX, response to previous ADT, and number of DTX cycles 
received. As shown in Table 2, there was no difference in ad-
Table 1. Patient Demographics
DTX DTX+ADT p value
Number of patients 21 26 NS
Age (yrs) 69 (67–74) 68 (63–72) 0.459
BMI (kg/m2) 24.0 (22.5–25.4) 24.2 (23.3–26.6) 0.708
ECOG PS ≥1, n (%) 8 (38.1) 15 (57.7) 0.181
Gleason score at diagnosis, n (%)
≤8 8 (38.1) 8 (30.8) 0.598
≥9 13 (61.9) 18 (69.2) 0.598
Clinical T stage at diagnosis, n (%)
≤T3 14 (66.7) 15 (57.7) 0.529
T4 7 (33.3) 11 (42.3) 0.529
Clinical N stage at diagnosis, n (%)
N1 13 (61.9) 14 (53.8) 0.579
Prior treatment, n (%)
Radical prostatectomy 5 (23.8) 6 (23.1) 1.000
Definitive EBRT 0 (0.0) 1 (3.8) 1.000
Palliative EBRT 7 (33.3) 9 (34.6) 0.927
Duration of ADT prior to DTX 12 (7–32.5) 10.5 (7–31.5) 0.464
Response to primary ADT
PSA nadir (ng/mL) 2.3 (0.4–14.5) 0.7 (0.2–7.8) 0.380
PSA velocity (ng/mL/yr) 28.9 (6.7–252.1) 33.5 (14.6–158.9) 0.906
PSA doubling time (ng/mL/yr) 0.16 (0.11–0.42) 0.18 (0.09–0.30) 0.700
Laboratory values
PSA at diagnosis (ng/mL) 68.9 (29.7–449.0) 85.2 (25.4–262.0) 0.881
PSA at CRPC diagnosis (ng/mL) 41.5 (26.9–112.0) 42.2 (28.8–173.4) 0.966
Hb (g/dL) 11.6 (10.8–12.9) 11.9 (10.9–13.0) 0.676
NLR 2.06 (1.39–3.64) 2.28 (1.57–4.13) 0.341
Albumin (g/dL) 4.1 (3.8–4.6) 4.2 (3.6–4.4) 0.772
Number of DTX cycles 7 (6–11) 9.5 (5–12) 0.643
Extent of disease at CRPC diagnosis, n (%)
Bone metastasis 18 (85.7) 25 (96.2) 0.311
Lymph node metastasis 15 (71.4) 17 (65.4) 0.659
Lung or liver metastasis 1 (4.8) 1 (3.8) 1.000
DTX, docetaxel-based chemotherapy; ADT, androgen deprivation therapy; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; PS, performance 
status; EBRT, external-beam radiation therapy; PSA, prostate-specific antigen; CRPC, castration-resistant prostate cancer; Hb, hemoglobin; NLR, neutrophil-to-
lymphocyte ratio.
Data are median (interquartile range) and number (%).
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verse events between the two groups. The reasons for discon-
tinuation of treatment are outlined in Table 3.
The median follow-up period was 24.0 months (IQR 12.0–
37.0) for the entire cohort, 23.0 months (IQR 13.5–32.5) for the 
DTX+ADT group, and 24.0 months (IQR 11.5–40.0) for the DTX 
group. Overall, 22 patients expired at the final follow-up, and 
the reason for patient mortality was PCa-related death in all pa-
tients.
The median bPFS was 8.0 months (95% CI 6.854–9.146) in 
the DTX+ADT group and 5.0 months (95% CI 4.128–5.872) in 
the DTX group. Kaplan-Meier analysis revealed a significant 
association between concurrent administration of ADT and 
prolonged bPFS (log-rank p=0.044) (Fig. 1). In univariable and 
multivariable Cox regression analyses, the number of DTX cy-
cles was the only significant predictor of bPFS (Table 4).
The median rPFS was 9.0 months (95% CI 4.003–13.997) in 
the DTX+ADT group and 6.0 months (95% CI 4.206–7.794) in 
the DTX group. Kaplan-Meier analysis revealed a significant 
association between concurrent administration of ADT and 
prolonged rPFS (log-rank p=0.036) (Fig. 2). On univariable Cox 
regression analysis, the number of DTX cycles and concurrent 
administration of ADT were significantly associated with rPFS, 
and concurrent administration of ADT was the only signifi-
Table 2. Adverse Events during DTX
Overall DTX DTX+ADT p value
CTCAE grade ≤2, n (%)
Thrombocytopenia 1 (2.1) 1 (4.8) 0 (0.0) 0.266
Anemia 8 (17.0) 3 (14.3) 5 (19.2) 0.657
Aspartate/alanine aminotransferase increased 14 (29.8) 5 (23.8) 9 (34.6) 0.426
Nausea & vomiting 29 (61.7) 15 (71.4) 14 (53.8) 0.223
Diarrhea 9 (19.1) 6 (28.6) 3 (11.5) 0.144
Constipation 13 (27.7) 8 (38.1) 5 (19.2) 0.155
Peripheral neuropathy 7 (14.9) 3 (14.3) 4 (15.4) 0.917
Dry mouth 14 (29.8) 8 (38.1) 6 (23.1) 0.268
Dry eye 12 (25.5) 7 (33.3) 5 (19.2) 0.275
Edema limbs 6 (12.8) 2 (9.5) 4 (15.4) 0.554
Myalgia 11 (23.4) 6 (28.6) 5 (19.2) 0.457
CTCAE grade ≥3, n (%)
Febrile neutropenia 8 (17.0) 4 (19.0) 4 (15.4) 0.742
Anemia 1 (2.1) 0 (0.0) 1 (3.8) 0.369
Nausea & vomiting 2 (4.3) 2 (9.5) 0 (0.0) 0.112
Peripheral neuropathy 2 (4.3) 0 (0.0) 2 (7.7) 0.199
Fatigue 2 (4.3) 1 (4.8) 1 (3.8) 0.878
CTCAE, common terminology criteria for adverse events; DTX, docetaxel-based chemotherapy; ADT, androgen deprivation therapy.
Table 3. Reasons for Discontinuation of DTX
Overall DTX DTX+ADT p value
Treatment toxicity, n (%) 15 (31.9) 7 (33.3) 8 (30.8) 0.851
Neutropenia 8 (17.0) 4 (19.0) 4 (15.4)
Anemia 1 (2.1) 0 (0.0) 1 (3.8)
Nausea & vomiting 2 (4.3) 2 (9.5) 0 (0.0)
Peripheral neuropathy 2 (4.3) 0 (0.0) 2 (7.7)
Fatigue 2 (4.3) 1 (4.8) 1 (3.8)
Disease progression, n (%) 19 (40.4) 10 (47.6) 9 (34.6) 0.366
Planned, n (%) 9 (19.1) 3 (14.3) 6 (23.1) 0.711
Death, n (%) 2 (4.3) 0 (0.0) 2 (7.7) 0.495
Patient refusal, n (%) 2 (4.3) 1 (4.8) 1 (3.8) 1.000
DTX, docetaxel-based chemotherapy; ADT, androgen deprivation therapy.
Fig. 1. Kaplan-Meier curve of biochemical progression-free survival. DTX, 
docetaxel-based chemotherapy; ADT, androgen deprivation therapy.
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cant predictor in multivariable analysis (Table 5).
The median OS was 42.0 months (95% CI 19.677–64.323) 
and 38.0 months (95% CI 7.752–68.243) in the DTX+ADT and 
DTX groups, respectively (log-rank p=0.796) (Fig. 3). On mul-
tivariable analysis, Hb level at the time of DTX initiation was 
associated with OS (Table 6).
DISCUSSION
DTX has been a standard chemotherapy treatment for CRPC 
since 2004, and both the SWOG 99-16 study and the Taxanes 
(TAX) 327 study demonstrated the superiority of DTX over mi-
toxantrone.27,28 The patients enrolled in both the SWOG 99-16 
and TAX 327 trials continued on ADT due to the possible detri-
mental effects of its discontinuation. AR activation and enzy-
matic androgen synthesis are potential mechanisms of CRPC, 
and these mechanisms can increase the sensitivity of neoplas-
tic cells to very low concentrations of testosterone.6-14 A study 
related to abiraterone acetate revealed that reducing serum tes-
tosterone to undetectable levels was correlated with extended 
survival for patients with mCRPC.29 Organizations such as the 
American Society of Clinical Oncology, the National Compre-
hensive Cancer Network, and others also recommend that ADT 
should be continued in nonorchiectomized CRPC patients 
Table 4. Associated Baseline Factors of Biochemical Progression-Free Survival via Univariable and Multivariable Analyses
Univariable analysis Multivariable analysis
HR (95% CI) p value HR (95% CI) p value
Age 1.009 (0.968–1.052) 0.680
BMI 0.938 (0.831–1.059) 0.302
ECOG PS ≥1 1.042 (0.572–1.898) 0.893
Gleason score 
≤8 1.356 (0.697–2.638) 0.370
≥9 0.738 (0.379–1.436) 0.370
Clinical T stage 
≥T3 0.907 (0.484–1.699) 0.760
T4 1.103 (0.589–2.065) 0.760
Clinical N stage 
N1 0.736 (0.392–1.382) 0.340
PSA at diagnosis 1.000 (1.000–1.000) 0.647
PSA at CRPC diagnosis 1.000 (1.000–1.001) 0.307
Hb 0.904 (0.738–1.107) 0.328
NLR 1.027 (0.944–1.117) 0.534
Albumin 1.732 (0.797–3.765) 0.165
Prior radical prostatectomy 0.728 (0.355–1.494) 0.387
Prior palliative EBRT 1.292 (0.675–2.472) 0.439
DTX+ADT 0.583 (0.316–1.075) 0.084
Number of DTX cycles 0.876 (0.796–0.964) 0.007 0.876 (0.796–0.964) 0.007
Extent of disease 
Bone metastasis 0.855 (0.303–2.414) 0.767
Lymph node metastasis 1.087 (0.563–2.096) 0.804
Lung or liver metastasis 0.788 (0.188–3.304) 0.745
HR, hazard ratio; CI, confidence interval; DTX, docetaxel-based chemotherapy; ADT, androgen deprivation therapy; BMI, body mass index; ECOG, Eastern Coop-
erative Oncology Group; PS, performance status; EBRT, external-beam radiation therapy; PSA, prostate-specific antigen; CRPC, castration-resistant prostate can-
cer; Hb, hemoglobin; NLR, neutrophil-to-lymphocyte ratio.
Fig. 2. Kaplan-Meier curve of radiographic progression-free survival. DTX, 
docetaxel-based chemotherapy; ADT, androgen deprivation therapy.
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during clinical trials for the same reason.
There have been several studies on the effectiveness of con-
tinued ADT in CRPC patients under cytotoxic chemotherapy; 
however, the results have been inconsistent. Taylor, et al.19 ex-
amined data from 341 patients enrolled in ECOG trials and 
found that patients who maintained castrate levels of testos-
terone had a longer median survival of 2 months. On the other 
hand, Hussain, et al.20 analyzed data from 205 patients with 
CRPC enrolled in SWOG phase II chemotherapy trials, and 
there was no difference in median survival between patients 
who maintained castrate levels of testosterone and those who 
did not. Recently, a retrospective study was published on pa-
tients with CRPC who were treated with DTX, and clinical 
outcomes were not significantly different between patients 
who received concurrent ADT and those who did not.30
In our study, the rPFS and bPFS rates were significantly bet-
ter in the DTX+ADT group than in the DTX group; however, 
they did not show efficacy for OS, which has been considered 
the most important endpoint for the evaluation of new treat-
ments in oncology.31 Death is clinically important, objective, 
and easily defined. However, OS is associated with several 
drawbacks, which can in turn lead to inappropriate conclu-
sions. First, it requires a long-term follow-up period and a large 
number of patients to detect realistic OS, as it may not be ap-
Table 5. Associated Baseline Factors of Radiographic Progression-Free Survival via Univariable and Multivariable Analyses
Univariable analysis Multivariable analysis
HR (95% CI) p value HR (95% CI) p value
Age 1.024 (0.979–1.070) 0.301
BMI 0.995 (0.879–1.127) 0.938
ECOG PS ≥1 0.720 (0.394–1.317) 0.287
Gleason score 
≤8 1.363 (0.725–2.559) 0.336
≥9 0.734 (0.391–1.379) 0.336
Clinical T stage 
≤T3 1.620 (0.861–3.048) 0.134
T4 0.617 (0.328–1.161) 0.134
Clinical N stage 
N1 0.788 (0.435–1.429) 0.433
PSA at diagnosis 1.000 (1.000–1.000) 0.695
PSA at CRPC diagnosis 1.001 (1.000–1.001) 0.120
Hb 0.913 (0.737–1.131) 0.406
NLR 0.955 (0.879–1.039) 0.283
Albumin 0.853 (0.403–1.808) 0.679
Prior radical prostatectomy 1.189 (0.596–2.372) 0.623
Prior palliative EBRT 1.306 (0.696–2.452) 0.406
DTX+ADT 0.550 (0.300–1.007) 0.053 0.525 (0.284–0.970) 0.040
Number of DTX cycles 0.948 (0.884–1.017) 0.134 0.940 (0.872–1.013) 0.104
Extent of disease 
Bone metastasis 1.136 (0.349–3.700) 0.832
Lymph node metastasis 1.349 (0.708–2.572) 0.363
Lung or liver metastasis 1.385 (0.331–5.796) 0.656
HR, hazard ratio; CI, confidence interval; DTX, docetaxel-based chemotherapy; ADT, androgen deprivation therapy; BMI, body mass index; ECOG, Eastern Coop-
erative Oncology Group; PS, performance status; EBRT, external-beam radiation therapy; PSA, prostate-specific antigen; CRPC, castration-resistant prostate can-
cer; Hb, hemoglobin; NLR, neutrophil-to-lymphocyte ratio.
Fig. 3. Kaplan-Meier curve of overall survival. DTX, docetaxel-based 
chemotherapy; ADT, androgen deprivation therapy.
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propriate for evaluating the superiority of a treatment in small-
scale retrospective studies. Second, potential differences in 
OS between the experimental and control groups could be 
masked by the use of second-line therapy after tumor progres-
sion on first-line therapy. In our study, excluding expired pa-
tients, various types of second line chemotherapies were ad-
ministrated to the disease-progressed patients. Third, OS can 
be influenced by survival post-progression. According to a 
study of Broglio and Berry,32 a lack of statistical significance in 
OS does not imply a lack of improvement in OS for clinical tri-
als with a PFS benefit, particularly for diseases with long me-
dian survival post-progression. If there is long-term survival 
after disease progression, there is also the potential for multi-
ple additional treatments, which can dilute the treatment ef-
fect. Broglio and Berry32 suggested that longer periods of sur-
vival post-progression (i.e., 12 months), would cause statistical 
significance in OS to be decreasingly likely. The median sur-
vival post-progressions periods were 13.0 and 18.0 months (ra-
diographic and biochemical, respectively) in our study, thus, 
these long periods may have potentially affected OS. There-
fore, it was not appropriate to evaluate the efficacy of continu-
ing ADT based solely on OS in our study.
As described above, use of OS as the primary endpoint is of-
ten limited, and it may be helpful to use an appropriate surro-
gate endpoint in such cases. PFS is an attractive endpoint as a 
surrogate of survival, given that it can be used in studies with 
small sample sizes, as the definition of PFS includes a greater 
number of events than that of OS. Moreover, progression of a 
disease occurs before survival can be measured; thus, PFS is 
not confounded by the effects of interim treatments. Due to 
these advantages, the European Agency for the Evaluation of 
Medical Products accepts a prolongation in the time to pro-
gression as a primary requirement for new drug registration in 
the European Union.33 Particularly in recent years, radiograph-
ic progression defined using the PCWG-2 criteria has emerged 
as a feasible surrogate endpoint of OS. Sonpavde, et al.34 showed 
that rPFS was significantly associated with OS in patients with 
mCRPC who received first-line DTX or post-docetaxel therapy. 
Kendall’s τ was 0.50 (p<0.001) in a setting of docetaxel-based 
therapy and 0.34 (p<0.001) in the post-docetaxel setting for as-
sociation between rPFS and OS. Unlike radiographic progres-
sion, PSA response has not been demonstrated to produce ro-
bust results as a surrogate endpoint of OS in studies on the 
survival outcomes of mCRPC after chemotherapy. PSA cannot 
Table 6. Associated Baseline Factors of Overall Survival via Univariable and Multivariable Analyses
Univariable analysis Multivariable analysis
HR (95% CI) p value HR (95% CI) p value
Age 1.036 (0.969–1.109) 0.301
BMI 0.950 (0.806–1.120) 0.543
ECOG PS ≥1 1.121 (0.485–2.592) 0.789
Gleason score 
≤8 0.772 (0.301–1.980) 0.590
≥9 1.295 (0.505–3.322) 0.590
Clinical T stage 
≤T3 0.910 (0.391–2.118) 0.826
T4 1.099 (0.472–2.558) 0.826
Clinical N stage 
N1 1.302 (0.545–3.113) 0.552
PSA at diagnosis 0.999 (0.997–1.000) 0.130 0.999 (0.997–1.000) 0.138
PSA at CRPC diagnosis 1.001 (1.000–1.003) 0.012
Hb 0.610 (0.453–0.822) 0.001 0.532 (0.381–0.744) <0.001
NLR 1.039 (0.938–1.151) 0.465
Albumin 0.391 (0.144–1.056) 0.064
Prior radical prostatectomy 0.656 (0.222–1.945) 0.447
Prior palliative EBRT 1.842 (0.779–4.355) 0.164
DTX+ADT 1.116 (0.481–2.591) 0.798
Number of DTX cycles 1.012 (0.938–1.092) 0.759
Extent of disease 
Bone metastasis 0.487 (0.143–1.656) 0.249
Lymph node metastasis 1.946 (0.716–5.281) 0.192
Lung or liver metastasis 1.175 (0.156–8.878) 0.876
HR, hazard ratio; CI, confidence interval; DTX, docetaxel-based chemotherapy; ADT, androgen deprivation therapy; BMI, body mass index; ECOG, Eastern Coop-
erative Oncology Group; PS, performance status; EBRT, external-beam radiation therapy; PSA, prostate-specific antigen; CRPC, castration-resistant prostate can-
cer; Hb, hemoglobin; NLR, neutrophil-to-lymphocyte ratio.
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differentiate variability in tumor response across different dis-
ease sites.35 Moreover, PSA surge and flare up phenomena, wh-
ich lead to transient PSA elevation following chemotherapy, are 
not uncommon in patients with CRPC who respond to chemo-
therapy.36-38 It is reported that these phenomena occur between 
1 and 8 weeks following a drop in the level of serum PSA.39 For 
this reason, we only included patients who continued for at le-
ast three cycles of DTX in this study.
The PCWG-2 recommends that early rising PSA levels should 
not be used as the sole criterion for discontinuing treatment 
on the basis of the description above.24 At the Advanced Pros-
tate Cancer Consensus Conference, held in 2015, there was 
consensus (82% of the panel) that at least two of three criteria 
(PSA progression, radiographic progression and clinical dete-
rioration) should be fulfilled to stop treatment of patients with 
advanced PCa.40 In this study, there was no patient who stopped 
DTX for PSA progression alone, and there was no significant 
difference in the respective reasons for discontinuing DTX 
between the two groups (Table 2). Additionally, there was no 
patient in the DTX+ADT group who stopped DTX due to the 
adverse effects of continuing ADT, such as coronary heart dis-
ease, myocardial infarction, bone fracture, or diabetes.
The present study was primarily designed to assess the im-
pact of concurrent administration of ADT and DTX in patients 
with mCRPC using rPFS as a primary endpoint. None of the 
patients in this study had received cytotoxic chemotherapy be-
fore DTX; thus, our study was able to provide more accurate 
results. However, there were several limitations to this study: 
1) our data were retrospectively collected at a single center, 
causing the results to be sensitive to selection bias; 2) serum 
testosterone measurements were not performed for all patients, 
and the limited number of samples precluded a meaningful 
analysis; and 3) this study involved a small sample size due to 
the relative rarity of chemotherapy-naive patients without a 
dose reduction of docetaxel. The limited sample size may have 
precluded a strong conclusion.
In this study involving men with mCRPC, the combined use 
of ADT and DTX improved rPFS and bPFS. Mentioned previ-
ously, there were several limitations related to using OS to eval-
uate the efficacy of treatment in our study, and rPFS could be a 
clinically meaningful surrogate of survival for several reasons. 
Therefore, the results of our study suggest that the combined 
use of ADT and DTX is superior to DTX alone.
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